Tag: DXB

ASX biotech stocks COVID-19 life science

ASX biotech stocks benefiting from the COVID-19 story

Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Natural...
Dimerix ASX DXB diabetic kidney disease DMX-200 drug

Dimerix unveils ‘tremendous’ top-line results for lead drug in treating rare kidney disorder

Drug development company Dimerix (ASX: DXB) emerged from a trading halt today with top-line results from its phase 2a ACTION study into DMX-200 for treatment of focal segmental glomerulosclerosis (FSG...
Dimerix ASX DXB REMAP-CAP lead drug candidate Acute Respiratory Distress Syndrome ARDS COVID-19

Dimerix’s lead drug candidate to be included in key clinical study for COVID-19 respiratory patients

A lead drug candidate developed by clinical-stage biopharmaceutical company Dimerix Limited (ASX: DXB) has been selected for inclusion in a global study aimed at treating patients with acute respirato...
Dimerix ASX DXB DMX Therapeutic Goods Administration TGA Special Access Scheme SAS

Patients continue Dimerix’s DMX-200 treatment post-trial under TGA scheme

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) received an operational boost earlier today after announcing that patients from phase 2 trials will continue treatment with its DMX-200 adju...
Dimerix ASX DXB DMX-700 Chronic Obstructive Pulmonary Disease COPD drug pipeline

Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease

Clinical-stage biopharmaceutical company Dimerix (ASX: DXB) has announced plans to target the development of what it calls “an important new discovery” in the treatment of chronic obstructive pulmonar...
Dimerix ASX DXB orphan drug designation EU Europe DMX-200 kidney Dr Nina Webster

Dimerix receives orphan drug designation in Europe for DMX-200

Drug development company Dimerix (ASX: DXB) has confirmed that the European Commission (EC) has approved its DMX-200 drug to be used as an “orphan medicinal product” for the treatment of Focal Segment...
Proteomics International Dimerix ASX PIQ DXB kidney disease

Proteomics International and Dimerix join forces to combat kidney disease

Medical technology company Proteomics International (ASX: PIQ) has teamed up with biotech stock Dimerix (ASX: DXB) to investigate the potential of their combined technology in treating kidney disease....
Dimerix ASX DXB positive kidney disease trial shares rally

Dimerix shares rally on positive results from kidney disease trial

Dimerix Limited (ASX: DXB) shares have rallied over 36% as the company reported positive safety and efficacy data following its now completed 27 patient Phase 2a proof of concept, dose escalation stud...